Topic:Advances in the Research and Development of Anti-HIV Chemotherapy via Multiple-targeted Intervention
Speaker:Prof. LONG Ya-Qiu , Professor, Principal Investigator , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Abstract:
The current treatment strategy for HIV-1 infected patients consists of highly active antiretroviral Therapy (HAART). HAART regimens are comprised of drug cocktails that include a combination of agents targeting the viral enzymes protease (PR) and reverse transcriptase (RT), and are initially successful at reducing viral loads to below detectable levels. However, prolonged therapy is associated with the emergence of drug resistant viral strains and cytotoxicity issues, which demands a continued effort toward the discovery of novel inhibitors to reduce the progress of drug-resistance and toxicity. Herein in combination with our work in the design and discovery of HIV-1 integrase inhibitors and CCR5 antagonists, we will report the new strategies and development in the drug discovery of anti-HIV therapy, and introduced the novel mechanism of action and the structure of newly FDA-approved anti-AIDS drugs.
